Haupt DW - Search Results

1

Metabolic risks and effects of atypical antipsychotic treatment.

Haupt DW, Kane JM. Haupt DW, et al. J Clin Psychiatry. 2007 Oct;68(10):e24. doi: 10.4088/jcp.1007e24. J Clin Psychiatry. 2007. PMID: 17960957

2

The metabolic effects of antipsychotic medications.

Newcomer JW, Haupt DW. Newcomer JW, et al. Among authors: haupt dw. Can J Psychiatry. 2006 Jul;51(8):480-91. doi: 10.1177/070674370605100803. Can J Psychiatry. 2006. PMID: 16933585 Review.

3

Hyperglycemia and antipsychotic medications.

Haupt DW, Newcomer JW. Haupt DW, et al. J Clin Psychiatry. 2001;62 Suppl 27:15-26; discussion 40-1. J Clin Psychiatry. 2001. PMID: 11806485 Review.

4

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.

Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Newcomer JW, et al. Among authors: haupt dw. Arch Gen Psychiatry. 2002 Apr;59(4):337-45. doi: 10.1001/archpsyc.59.4.337. Arch Gen Psychiatry. 2002. PMID: 11926934 Review.

5

Differential metabolic effects of antipsychotic treatments.

Haupt DW. Haupt DW. Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S149-55. doi: 10.1016/j.euroneuro.2006.06.003. Epub 2006 Jul 25. Eur Neuropsychopharmacol. 2006. PMID: 16872808 Review.

6

Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.

Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Haupt DW, et al. Am J Psychiatry. 2009 Mar;166(3):345-53. doi: 10.1176/appi.ajp.2008.08030383. Epub 2009 Jan 15. Am J Psychiatry. 2009. PMID: 19147694

7

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW. Haupt DW, et al. Neuropsychopharmacology. 2005 Jan;30(1):184-91. doi: 10.1038/sj.npp.1300563. Neuropsychopharmacology. 2005. PMID: 15367925 Clinical Trial.

8

Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients.

Haupt DW, Fahnestock PA, Flavin KA, Schweiger JA, Stevens A, Hessler MJ, Maeda J, Yingling M, Newcomer JW. Haupt DW, et al. Neuropsychopharmacology. 2007 Dec;32(12):2561-9. doi: 10.1038/sj.npp.1301392. Epub 2007 Mar 21. Neuropsychopharmacology. 2007. PMID: 17375138

9

Impact of medical comorbidity on medication management of schizophrenia.

Haupt DW. Haupt DW. CNS Spectr. 2007 Dec;12(12 Suppl 21):15-7. doi: 10.1017/s1092852900015960. CNS Spectr. 2007. PMID: 18389928 Review. No abstract available.

10

Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.

Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH. Casey DE, et al. Among authors: haupt dw. J Clin Psychiatry. 2004;65 Suppl 7:4-18; quiz 19-20. J Clin Psychiatry. 2004. PMID: 15151456 Free article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters